EBACU (European Biotech Acquisition) Enterprise Value : $0.00 Mil (As of Apr. 29, 2025)

European Biotech Acquisition Enterprise Value Chart

Competitive Comparison of European Biotech Acquisition's Enterprise Value

For the Shell Companies subindustry, European Biotech Acquisition's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

European Biotech Acquisition's Enterprise Value Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, European Biotech Acquisition's Enterprise Value distribution charts can be found below:

* The bar in red indicates where European Biotech Acquisition's Enterprise Value falls into.

European Biotech Acquisition Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

European Biotech Acquisition's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

European Biotech Acquisition's Enterprise Value for the quarter that ended in Dec. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

European Biotech Acquisition  (NAS:EBACU) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

European Biotech Acquisition's EV-to-EBIT for today is

European Biotech Acquisition's current Enterprise Value is $0.00 Mil.
European Biotech Acquisition's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.82 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

European Biotech Acquisition's EV-to-EBITDA for today is:

European Biotech Acquisition's current Enterprise Value is $0.00 Mil.
European Biotech Acquisition's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.82 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

European Biotech Acquisition's EV-to-Revenue for today is:

European Biotech Acquisition's current Enterprise Value is $0.00 Mil.
European Biotech Acquisition's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

European Biotech Acquisition's EV-to-FCF for today is:

European Biotech Acquisition's current Enterprise Value is $0.00 Mil.
European Biotech Acquisition's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

European Biotech Acquisition Enterprise Value Related Terms

Thank you for viewing the detailed overview of European Biotech Acquisition's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

European Biotech Acquisition Business Description